home / stock / ipha / ipha news

IPHA News and Press, Innate Pharma S.A. From 02/17/25

Stock Information
Company Name: Innate Pharma S.A.
Stock Symbol: IPHA
Market: NASDAQ
Website: innate-pharma.com
Menu
IPHA IPHA Quote IPHA Short IPHA News IPHA Articles IPHA Message Board
Get IPHA Alerts

News, Short Squeeze, Breakout and More Instantly...
IPHA - Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary Syndrome

Designation is based on TELLOMAK Phase 2 results demonstrating efficacy and a favorable safety profile in patients with advanced Sézary syndrome heavily pre-treated, post- mogamulizumab. Breakthrough Therapy Designation is intended to accelerate the development and regulatory rev...
IPHA - Innate Pharma Announces First Patient Dosed in Phase 1 Study of Its Nectin-4 Targeting Antibody Drug Conjugate IPH4502 in Selected Advanced Solid Tumors

IPH4502 is a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4 Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced the first pat...

IPHA - Innate Pharma Announces Nectin-4 Antibody Drug Conjugate Investor and Analyst Event in New York

Innate Pharma to highlight IPH4502, its lead Nectin-4 Antibody Drug Conjugate (ADC) program at clinical stage Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) will host an event for institut...

IPHA - Number of Shares and Voting Rights of Innate Pharma as of December 31, 2024

Regulatory News: Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “ AMF ”) General Regulation, Innate Pharma SA (Euronext Pari...
IPHA -  Innate Pharma Announces Transformative Strategy to Accelerate Growth

Strategy anchored on early clinical development of proprietary assets with single-agent potential: Drive innovation with first-in-class ANKET ® NK-cell engager Platform Accelerate development of differentiated Antibody-Drug Conjugates Advance current late-stage as...

Previous 10 Next 10